Page 4 - Nasdaq Allo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company...

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Investment analysts at HC Wainwright upped their Q3 2023 earnings per share estimates for shares of Allogene Therapeutics in a report issued on Monday, August 7th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.48) for the quarter, up […]

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Investment analysts at William Blair boosted their Q3 2023 earnings estimates for Allogene Therapeutics in a research note issued on Thursday, August 3rd. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of ($0.53) for the quarter, up from their prior […]

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $4.27 and last traded at $4.31, with a volume of 1199577 shares trading hands. The stock had previously closed at $4.59. Analyst Upgrades and Downgrades ALLO has been the topic […]

Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price target decreased by Truist Financial from $20.00 to $18.00 in a research report released on Wednesday, FlyOnTheWall reports. A number of other equities analysts also recently commented on ALLO. EF Hutton Acquisition Co. I reaffirmed a buy rating and set a $15.00 price objective on shares […]